Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)
Close on Nov 13, 2026Market cap $2.36BP/E –Yield –
Beam Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Beam Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $408.66M, up 3.1% year over year. For fiscal 2025 it was $409.62M, up 11.4% from the year before. The highest annual figure on record is $437.38M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $409.62M | +11.4% |
| FY2024 | Dec 31, 2024 | $367.56M | -16.0% |
| FY2023 | Dec 31, 2023 | $437.38M | +40.4% |
| FY2022 | Dec 31, 2022 | $311.59M | -19.5% |
| FY2021 | Dec 31, 2021 | $387.09M | +275.2% |
| FY2020 | Dec 31, 2020 | $103.18M | +88.9% |
| FY2019 | Dec 31, 2019 | $54.62M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $95.10M | -6.5% |
| Q1 FY2026 | Mar 31, 2026 | $104.52M | +5.8% |
| Q4 FY2025 | Dec 31, 2025 | $99.28M | -2.1% |
| Q3 FY2025 | Sep 30, 2025 | $109.77M | +16.5% |
| Q2 FY2025 | Jun 30, 2025 | $101.76M | +16.9% |
| Q1 FY2025 | Mar 31, 2025 | $98.82M | +16.5% |
| Q4 FY2024 | Dec 31, 2024 | $101.44M | -27.6% |
| Q3 FY2024 | Sep 30, 2024 | $94.26M | -5.8% |
| Q2 FY2024 | Jun 30, 2024 | $87.04M | -10.8% |
| Q1 FY2024 | Mar 31, 2024 | $84.82M | -14.9% |
| Q4 FY2023 | Dec 31, 2023 | $140.08M | +62.2% |
| Q3 FY2023 | Sep 30, 2023 | $100.05M | +17.3% |
| Q2 FY2023 | Jun 30, 2023 | $97.61M | +30.9% |
| Q1 FY2023 | Mar 31, 2023 | $99.65M | +52.3% |
| Q4 FY2022 | Dec 31, 2022 | $86.34M | -10.8% |
| Q3 FY2022 | Sep 30, 2022 | $85.29M | +56.1% |
| Q2 FY2022 | Jun 30, 2022 | $74.56M | +63.6% |
| Q1 FY2022 | Mar 31, 2022 | $65.41M | -65.6% |
| Q4 FY2021 | Dec 31, 2021 | $96.78M | +198.2% |
| Q3 FY2021 | Sep 30, 2021 | $54.62M | +83.1% |
| Q2 FY2021 | Jun 30, 2021 | $45.58M | +135.5% |
| Q1 FY2021 | Mar 31, 2021 | $190.11M | +782.2% |
| Q4 FY2020 | Dec 31, 2020 | $32.45M | +60.5% |
| Q3 FY2020 | Sep 30, 2020 | $29.83M | +137.8% |
| Q2 FY2020 | Jun 30, 2020 | $19.35M | +52.6% |
| Q1 FY2020 | Mar 31, 2020 | $21.55M | +134.8% |
| Q4 FY2019 | Dec 31, 2019 | $20.22M | – |
| Q3 FY2019 | Sep 30, 2019 | $12.54M | – |
| Q2 FY2019 | Jun 30, 2019 | $12.68M | – |
| Q1 FY2019 | Mar 31, 2019 | $9.18M | – |
See a number that looks wrong?